Vincenzi V, Fioroni E, Benvegnù B, De Angelis M, Bartolucci L, Gradoli C, Valori C
Minerva Med. 1985 May 12;76(19-20):919-21.
The influence of Verapamil, a calcium antagonist, on circulating levels of glucose, insulin and glucagon has been evaluated in 5 normal subjects and in 5 patients with non insulin-dependent diabetes (NIDDM). An oral glucose tolerance test was performed both in basal conditions and during intravenous infusion of the drug (5 mg/h). Administration of Verapamil didn't induce any significant change on the three parameters. The small decrease of glycemia in patients affected by NIDDM and treated with Verapamil was not related to reduction of glucagonemia.
在5名正常受试者和5名非胰岛素依赖型糖尿病（NIDDM）患者中，评估了钙拮抗剂维拉帕米对血糖、胰岛素和胰高血糖素循环水平的影响。在基础条件下以及静脉输注该药物（5毫克/小时）期间均进行了口服葡萄糖耐量试验。维拉帕米的给药并未引起这三个参数的任何显著变化。NIDDM患者接受维拉帕米治疗后血糖的小幅下降与胰高血糖素血症的降低无关。
